PMID- 36934264 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230601 IS - 1475-2867 (Print) IS - 1475-2867 (Electronic) IS - 1475-2867 (Linking) VI - 23 IP - 1 DP - 2023 Mar 18 TI - Exosomal MFI2-AS1 sponge miR-107 promotes non-small cell lung cancer progression through NFAT5. PG - 51 LID - 10.1186/s12935-023-02886-x [doi] LID - 51 AB - BACKGROUND: Non-small cell lung cancer is a heterogeneous disease driven by extensive molecular alterations. Exosomes are small vesicles with diameters ranging from 30 to 150 nm released by various cell types and are important mediators of information transmission in tumor cells. Exosomes contain proteins, lipids, and various types of nucleic acids, including miRNAs and even DNA and RNA. MFI2 Antisense RNA 1 (MFI2-AS1) is a long noncoding RNA known to promote cell proliferation, metastasis and invasion in a variety of malignancies. METHODS: The relative expression of MFI2-AS1 in NSCLC tissues was examined using RNA fluorescence in situ hybridization (FISH) staining. Transwell migration and wound healing assays were used to analyze cell migration and invasion abilities. Tube formation is used to assess angiogenic capacity. CCK8 was used to assess cell proliferation ability. RNA immunoprecipitation (RIP) experiments confirmed that MFI2-AS1 acts as a competing endogenous RNA (ceRNA) for miR-107. Dual-luciferase reporter assays were used to identify potential binding between MFI2-miRNA and target mRNA. In vivo experiments were performed by injecting exosomes into subcutaneous tumors to establish animal models. RESULT: Exosomal MFI2-AS1 increases NFAT5 expression by sponging miR-107, which in turn activates the PI3K/AKT pathway. We found that the MFI2-AS1/miR-107/NFAT5 axis plays an important role in exosome-mediated NSCLC progression, is involved in pre-metastatic niche formation, and can be used as a blood-based biomarker for NSCLC metastasis. CONCLUSION: We demonstrate that MFI2-AS1 is upregulated in exosomes secreted by metastatic NSCLC cells and can be transferred to HUVECs, promoting angiogenesis and migration. CI - (c) 2023. The Author(s). FAU - Xu, Jingwei AU - Xu J AD - Department of Cardiothoracic Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, 215002, China. FAU - Wang, Hui AU - Wang H AD - Department of Pulmonary and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, 26 Daoqian Street, Gusu District, Suzhou, 215002, China. FAU - Shi, Baoyu AU - Shi B AD - Department of Pulmonary and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, 26 Daoqian Street, Gusu District, Suzhou, 215002, China. FAU - Li, Ning AU - Li N AD - Department of Pulmonary and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, 26 Daoqian Street, Gusu District, Suzhou, 215002, China. FAU - Xu, Guopeng AU - Xu G AD - Department of Pulmonary and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, 26 Daoqian Street, Gusu District, Suzhou, 215002, China. FAU - Yan, Xiaopei AU - Yan X AD - Department of Pulmonary and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, 26 Daoqian Street, Gusu District, Suzhou, 215002, China. 497976246@qq.com. FAU - Xu, Li AU - Xu L AD - Department of Pulmonary and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, 26 Daoqian Street, Gusu District, Suzhou, 215002, China. wuxiaohan200901@sina.com. LA - eng PT - Journal Article DEP - 20230318 PL - England TA - Cancer Cell Int JT - Cancer cell international JID - 101139795 PMC - PMC10024841 OTO - NOTNLM OT - MFI2-AS1 OT - NFAT5 OT - Non-small cell lung cancer OT - Pre-metastatic niche formation OT - miR-107 COIS- The authors declare that there are no conflict of interests. EDAT- 2023/03/20 06:00 MHDA- 2023/03/20 06:01 PMCR- 2023/03/18 CRDT- 2023/03/19 00:25 PHST- 2022/04/14 00:00 [received] PHST- 2023/03/03 00:00 [accepted] PHST- 2023/03/19 00:25 [entrez] PHST- 2023/03/20 06:00 [pubmed] PHST- 2023/03/20 06:01 [medline] PHST- 2023/03/18 00:00 [pmc-release] AID - 10.1186/s12935-023-02886-x [pii] AID - 2886 [pii] AID - 10.1186/s12935-023-02886-x [doi] PST - epublish SO - Cancer Cell Int. 2023 Mar 18;23(1):51. doi: 10.1186/s12935-023-02886-x.